Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma. - Drucker,B.; Bacik,J.; Ginsberg,M.; Marion,S.; Russo,P.; Mazumdar,M.; Motzer,R. (Invest New Drugs, 2003)